Form 4: Biote Interim CEO Robert Peterson Receives Stock Options
Statement of Changes in Beneficial Ownership
Biote Corp. Interim CEO Robert Peterson was granted 206,746 stock options as part of his compensation package.
Summary
- Interim CEO Robert Peterson was granted 206,746 stock options on June 12, 2026.
- The options have an exercise price of $2.46 per share.
- The options are set to expire on June 11, 2036.
- Vesting schedule: 25% vests on June 12, 2027, with the remainder vesting in 36 equal monthly installments thereafter.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative filing regarding standard executive compensation.
Positives
- Alignment of executive interests with long-term shareholder value through equity-based compensation.
Negatives
- Granting of stock options results in potential future dilution for existing shareholders.
Risks
- The value of the granted options is dependent on the future performance of Biote Corp. Class A Common Stock.
Future Outlook
The filing does not provide specific forward-looking financial guidance, focusing instead on the terms of the executive equity grant.
Industry Context
StockSavvy.ai notes that equity grants for interim leadership are standard practice in the biotechnology and healthcare sectors to incentivize stability and performance during transitional periods.
Comparison to Industry Standards
- The use of a 4-year vesting schedule (1-year cliff followed by monthly vesting) is consistent with standard corporate governance practices for executive equity compensation.
Stakeholder Impact
- Shareholders may experience minor dilution upon the eventual exercise of these options.
Next Steps
- Vesting of 25% of the granted options on June 12, 2027.
Key Dates
| Date | Description |
|---|---|
| 2023-12-15 | Date of Power of Attorney execution for Robert Peterson. |
| 2026-06-12 | Transaction date of stock option grant. |
| 2027-06-12 | Initial vesting date for the granted stock options. |
| 2036-06-11 | Expiration date of the granted stock options. |
Keywords
Biote Corp, BTMD, Form 4, Executive Compensation, Stock Options, Insider Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.